Can I Take Calcium with Egrifta (Tesamorelin)?

The direct answer

Tesamorelin (Egrifta SV) and calcium supplements do not share a known metabolic pathway, transporter, or plasma-protein binding site. Tesamorelin is a 44-amino-acid peptide cleared by serum proteases within roughly half an hour of subcutaneous injection; it is not absorbed through the gut and has no mechanism for binding calcium ions the way, for example, an oral antibiotic can. The FDA prescribing information for Egrifta SV does not list calcium, or calcium-containing products, among its drug interactions. On that basis, there is no established requirement to separate the tesamorelin injection from a calcium dose. The more relevant clinical question is whether other drugs in a tesamorelin patient's regimen, or their underlying IGF-1 and bone status, change how calcium should be used, and that is a site-judgment and monitoring question rather than a strict interaction rule.

What tesamorelin is and why calcium comes up at all

Tesamorelin (brand name Egrifta SV) is a synthetic analog of growth-hormone-releasing hormone. It binds pituitary GHRH receptors and stimulates the body's own pulsatile release of growth hormone, which raises circulating insulin-like growth factor-1 (IGF-1). The FDA approved it in 2010 for a narrow indication: reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for general fat loss, bodybuilding, or anti-aging use, and using it outside the labeled population is off-label.

Growth hormone and IGF-1 are established regulators of bone remodeling and mineral metabolism in the broader endocrinology literature. That general physiology is the reason calcium is a reasonable question for anyone on tesamorelin, even though no direct drug interaction exists. It does not mean tesamorelin causes clinically significant changes in calcium levels; that specific claim has not been established in tesamorelin's own trial program as far as this review could verify, and readers should not assume it.

What is established, what is plausible, and what is not established

Established, from the FDA label:

• Tesamorelin is approved only for HIV-associated lipodystrophy in adults.
• The label does not list calcium as an interacting substance.
• IGF-1 monitoring is part of standard tesamorelin management, and the label describes dose adjustment when IGF-1 rises above the normal range for age and sex. The exact threshold and adjustment steps should be read directly from the current label rather than summarized numerically here, since label details are revised over time.

Plausible but not established for this specific drug-supplement pair:

• That tesamorelin-driven IGF-1 elevation meaningfully shifts calcium balance in patients already taking supplemental calcium. This is a reasonable extrapolation from general GH-IGF-1 physiology, not a finding reported in tesamorelin's own safety data as verified here.
• That tesamorelin has a bone-density benefit large enough to change calcium supplementation targets. Some GH-axis therapies have been studied for bone effects, but a verified, tesamorelin-specific bone mineral density result was not available to confirm for this draft, and any such figure from a prior version of this article should not be treated as reliable until checked against the primary trial publication.

Not established:

• Any case of clinically significant hypercalcemia caused by tesamorelin alone.
• Any dose-separation requirement between tesamorelin injections and oral calcium.

Where the real interaction risk sits: the rest of the regimen

Because HIV-associated lipodystrophy is often managed alongside other conditions, calcium's more consequential interactions in this population come from other drugs, not from tesamorelin itself.

Oral bisphosphonates. Alendronate, risedronate, and similar drugs are well documented to have reduced absorption when taken close to calcium or other divalent cations. Bisphosphonate labeling and pharmacy references consistently instruct patients to take the bisphosphonate first, on an empty stomach with plain water, and to wait a defined period (commonly at least 30 minutes, longer for some agents) before food or supplements including calcium. If a tesamorelin patient is also on a bisphosphonate for HIV-related bone loss, this separation matters more than anything involving tesamorelin.

Levothyroxine. Calcium carbonate reduces levothyroxine absorption when taken close together; standard practice is to separate them by several hours. Tesamorelin can modestly affect thyroid-axis measures according to its label, which makes this an area where a patient on both drugs should have their pharmacist confirm timing rather than assume it does not matter.

Fluoroquinolone or tetracycline antibiotics. Calcium and other divalent cations reduce absorption of these antibiotic classes; the usual guidance is to separate calcium by a couple of hours before or several hours after the antibiotic dose. This is a general pharmacy rule, not specific to tesamorelin.

None of these are tesamorelin-calcium interactions. They are calcium interactions with other drugs that happen to be common in the same patient population, and they are the reason a pharmacist review of the full medication list matters more than the narrow question in this article's title.

Calcium form and absorption considerations

Calcium carbonate needs stomach acid to dissolve and is best taken with food. Calcium citrate does not require acid and can be taken independent of meals, which is generally preferred for people on acid-suppressing drugs such as proton pump inhibitors, a common co-medication in HIV care. Neither form changes anything about tesamorelin timing.

Evidence-status interaction assessment

Monitoring that fits ordinary tesamorelin care

Standard tesamorelin management already includes periodic IGF-1 monitoring, per the FDA label, to guide dose continuation or adjustment. Serum calcium is not a labeled requirement for tesamorelin monitoring, but it is a routine, low-burden addition to periodic HIV metabolic labs, particularly for patients taking calcium doses above typical dietary-replacement amounts, or those with reduced kidney function, since impaired renal clearance changes how calcium and phosphate are handled regardless of tesamorelin use.

Contact a clinician promptly, rather than waiting for a scheduled lab, if new fatigue, muscle weakness, confusion, unusual thirst or urination, or symptoms of a kidney stone develop while taking both calcium and tesamorelin. These can reflect hypercalcemia, though they have several other possible causes and do not by themselves confirm a tesamorelin-calcium effect.

Who should get individualized guidance before adding calcium

• Anyone with primary hyperparathyroidism, granulomatous disease, prolonged immobilization, or a history of hypercalcemia
• Anyone with an eGFR below roughly 45 mL/min/1.73 m², where calcium and phosphate handling is already altered
• Anyone on an oral bisphosphonate, levothyroxine, or a fluoroquinolone/tetracycline, where the calcium interaction is with that drug, not tesamorelin
• Anyone whose tesamorelin prescriber has already flagged an elevated IGF-1 result

Bottom line

No mechanism links tesamorelin and calcium directly, and the FDA label does not restrict calcium use. The clinically meaningful work is elsewhere: separating calcium from bisphosphonates and levothyroxine if those are part of the regimen, keeping up with the IGF-1 monitoring already recommended for tesamorelin, and getting individualized advice if kidney function, parathyroid status, or prior hypercalcemia is in the picture. Readers should verify the current Egrifta SV label and their specific bisphosphonate or thyroid medication instructions with a pharmacist rather than rely on general timing rules alone.